On November 8, the US Food and Drug Administration approved Aucatzyl (obecabtagene autoleucel; obe-cel) from US biopharma Autolus Therapeutics, whose share rose more than 8% to 44.03 on the news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback